ZUNVEYL Drug Patent Profile

When do Zunveyl patents expire, and what generic alternatives are available?

Zunveyl is a drug marketed by Alpha Cognition and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-four patent family members in seventeen countries.

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this compound. Additional details are available on the benzgalantamine gluconate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zunveyl

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 16, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZUNVEYL

International Patents:	24
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ZUNVEYL?	ZUNVEYL excipients list
DailyMed Link:	ZUNVEYL at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZUNVEYL

NDA:

218549

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZUNVEYL

ZUNVEYL is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZUNVEYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes				Y
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No				Y
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-003	Jul 26, 2024		RX	Yes	No
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-003	Jul 26, 2024		RX	Yes	No				Y

International Patents for ZUNVEYL

When does loss-of-exclusivity occur for ZUNVEYL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Canada

China

Cyprus

Denmark

European Patent Office

Germany

Japan

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZUNVEYL around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022150917
Denmark	1940817
European Patent Office	1777222	Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs (Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment)
China	116761612	α-1062葡糖酸盐的固体形式 (Solid forms of alpha-1062 gluconate)
Germany	602006015338
Canada	2623114	AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
South Korea	20230131220	알파-1062 글루코네이트의 고체 형태